UroEdge™

Theranostics in Prostate Cancer

Theranostics is a precision medicine approach that combines molecular imaging with targeted radiopharmaceutical therapy to personalize cancer care. This learning center includes content on PSMA PET imaging, patient selection, radioligand therapy, multidisciplinary collaboration, and evolving clinical evidence in advanced prostate cancer.

Theranostics Learning Center

TitleSpeakerExcerptDate
Sequencing Lu-177 PSMA-directed RLTMichael J. Morris, MDThis expert panel, led by Dr. Michael Morris, with Drs. Jérémie Calais and Neal Shore, explores how Lu-177–PSMA therapy is moving earlier in prostate cancer care. 2025-12-292025
Candidates and Follow-Up for Lu-177 PSMAMichael J. Morris, MDAn expert panel reviews imaging criteria, candidate selection, and follow-up strategies for Lu-177 PSMA therapy, comparing VISION and TheraP trial frameworks.2025-12-292025
A PCa Case of PSA Recurrence After Retropubic RP, XRT & a Case of Diffusely mPCa Developing Castration ResistanceDavid S. Morris, MD, FACSExperts discuss sequencing of lutetium-177 PSMA after taxane chemotherapy and Radium-223 in advanced prostate cancer.2025-12-192025
A Case of CRPC Using PSMA PET Imaging & a Case of Gleason 9, PSA of 200, and Slowly Rising PSADavid S. Morris, MD, FACSExperts discuss sequencing of lutetium-177 PSMA therapy, chemotherapy, and targeted agents in advanced prostate cancer.2025-12-182025
Clinical Use of Lutetium-177–PSMA-617 for Metastatic Castrate Resistant Prostate CancerEvan Y. Yu, MDA clinical overview of Lutetium-177–PSMA-617 therapy with guidance on PSMA PET selection and safety monitoring.2025-12-182025
A PCa Case of PSA Rising After RP, Salvage XRT, ADT & a Case of Rising PSA After Triplet TherapyDavid S. Morris, MD, FACSExperts discuss PSMA PET–guided sequencing of systemic and radioligand therapy in advanced prostate cancer.2025-12-162025

Supported in part by Novartis.